Psychemedics Corporation (PMD)
Stock Price:
$4.89 USD
0.16 (3.38%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
27.02M |
| Revenue (ttm) |
35.39M |
| Net Income (ttm) |
756,000 |
| Shares Out |
5.53M |
| EPS (ttm) |
0.14 |
| PE Ratio |
34.93 |
| Forward PE |
n/a |
| Dividend |
$0.72 |
| Dividend Yield |
14.72% |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$4.89 |
| Previous Close |
$4.73 |
| Change ($) |
0.16 |
| Change (%) |
3.38% |
| Day's Open |
4.70 |
| Day's Range |
4.61 - 4.90 |
| Day's Volume |
35,449 |
| 52-Week Range |
4.51 - 10.69 |
More Stats
| Market Cap |
27.02M |
| Enterprise Value |
27.25M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
5.53M |
| Float |
4.65M |
| EPS (basic) |
0.13 |
| EPS (diluted) |
0.14 |
| FCF / Share |
0.29 |
| Dividend |
$0.72 |
| Dividend Yield |
14.72% |
| Earnings Yield |
2.86% |
| FCF Yield |
5.91% |
| Payout Ratio |
553.80% |
| Shares Short |
21,510 |
| Short Ratio |
0.63 |
| Short % of Float |
0.30% |
| Beta |
0.88 |
| PE Ratio |
34.93 |
| Forward PE |
n/a |
| P/FCF Ratio |
16.92 |
| PS Ratio |
0.76 |
| PB Ratio |
1.72 |
| Revenue |
35.39M |
| Operating Income |
1.81M |
| Net Income |
756,000 |
| Free Cash Flow |
1.60M |
| Net Cash |
-229,000 |
| Net Cash / Share |
-0.04 |
| Gross Margin |
46.46% |
| Operating Margin |
5.12% |
| Profit Margin |
2.10% |
| FCF Margin |
4.51% |
| ROA |
6.44% |
| ROE |
4.41% |
| ROIC |
9.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
32.0
Current: $4.89
High
32.0
Target: 32.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 37.68 | 42.67 | 39.70 | 38.98 | 26.98 | 29.21 | 26.87 | 25.22 | 24.09 | 20.11 |
| Revenue Growth | -11.71% | 7.49% | 1.85% | 44.5% | -7.64% | 8.69% | 6.53% | 4.71% | 19.8% | - |
| Gross Profit | 16.44 | 20.62 | 19.82 | 21.45 | 12.72 | 15.14 | 15.39 | 14.25 | 14.47 | 12.04 |
| Operating Income | 3.00 | 7.61 | 8.16 | 10.11 | 1.47 | 4.63 | 5.71 | 4.94 | 5.80 | 4.41 |
| Net Income | 1.54 | 4.58 | 6.12 | 6.68 | 1.51 | 3.21 | 3.81 | 2.98 | 3.49 | 2.61 |
| Shares Outstanding | 5.51 | 5.50 | 5.48 | 5.45 | 5.41 | 5.36 | 5.30 | 5.26 | 5.23 | 5.21 |
| Earnings Per Share | 0.28 | 0.83 | 1.10 | 1.22 | 0.28 | 0.60 | 0.72 | 0.57 | 0.67 | 0.50 |
| EPS Growth | -66.27% | -24.55% | -9.84% | 335.71% | -53.33% | -16.67% | 26.32% | -14.93% | 34% | - |
| Dividend Per Share | 0.72 | 0.69 | 0.60 | 0.60 | 0.60 | 0.60 | 0.60 | 0.60 | 0.48 | 0.48 |
| Dividend Growth | 4.35% | 15% | 0% | 0% | 0% | 0% | 0% | 25% | 0% | - |
| Operating Cash Flow | 4.31 | 7.93 | 9.15 | 9.27 | 4.58 | 4.46 | 5.95 | 3.09 | 3.94 | 3.30 |
| Capital Expenditures | -1.73 | -1.32 | -1.25 | -2.09 | -1.80 | -7.81 | -1.76 | -2.34 | -1.49 | -0.82 |
| Free Cash Flow | 2.58 | 6.61 | 7.90 | 7.18 | 2.78 | -3.35 | 4.19 | 0.75 | 2.45 | 2.48 |
| Cash & Equivalents | 7.28 | 7.97 | 8.17 | 3.94 | 2.69 | 3.61 | 3.97 | 3.07 | 5.56 | 5.74 |
| Total Debt | 5.97 | 1.63 | 3.38 | 3.38 | 5.89 | 6.25 | - | - | - | - |
| Net Cash / Debt | 1.32 | 6.35 | 4.79 | 0.56 | -3.20 | -2.64 | 3.97 | 3.07 | 5.56 | 5.74 |
| Assets | 27.53 | 24.97 | 26.51 | 25.03 | 22.04 | 24.08 | 16.55 | 14.12 | 13.80 | 11.84 |
| Liabilities | 10.71 | 6.23 | 7.89 | 9.43 | 10.36 | 11.24 | 4.27 | 2.90 | 2.77 | 2.09 |
| Book Value | 16.82 | 18.75 | 18.62 | 15.61 | 11.67 | 12.84 | 12.28 | 11.22 | 11.03 | 9.75 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Psychemedics Corporation |
| Country |
United States |
| Employees |
204 |
| CEO |
Raymond C. Kubacki |
Stock Information
| Ticker Symbol |
PMD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: PMD |
Description
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, opiates, synthetic cannabinoids, and benzodiazepines. Its testing results provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data that can show a pattern of individual drug use over a longer period-of-time. The company provides its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was founded in 1986 and is headquartered in Acton, Massachusetts.